A comparison of small-subunit ribosomal RNA gene sequences of bovine Babesia species transmitted by Haemaphysalis spp. in China

The ribosomal small-subunit RNA gene sequences of six Chinese Babesia stocks infective to cattle, including a Babesia bigemina isolate, a B. bovis isolate, two B. ovata isolates, a Babesia sp. Wenchuan isolate and a B. major isolate, were compared and analyzed. The target DNA segment was amplified by polymerase chain reaction and the product ligated into the pGEM-T Easy vector for sequencing. The length of the 18S rRNA gene of all Babesia species involved in this study varied between 1,653 and 1,693 bp. The phylogenetic trees were inferred based on the 18S rRNA sequence of the Chinese isolates as well as other species of Babesia available in GenBank. The results showed that the B. ovata transmitted by Haemaphysalis longicornis and Babesia sp. Wenchuan isolate were confined to the same group as B. ovata Korea, with an identity among them of >96.5%, while B. major transmitted by H. punctata was situated in another branch, and identity with other bovine Babesia species was less than 92.5%. B. ovata should, therefore, be a valid species, differing from B. major according to the 18S rRNA gene sequence.     

Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 Avian Influenza virus in chickens

There is an urgent need for identification of a new adjuvant capable of selectively promoting an efficient immune response for use with vaccines and especially subunit vaccines. Our pervious study showed that Bursopentine (BP5) is a novel immunomodulatory peptide and has the ability to significantly stimulate an antigen-specific immune response in mice. In this study, the potential adjuvant activities of BP5 were examined in chickens by coinjection of BP5 and an inactivated avian influenza virus (AIV) (A/Duck/Jiangsu/NJ08/05 [AIV H9N2 subtype]). The results suggested that BP5 markedly elevated serum hemagglutination inhibition (HI) titers and antigen-specific antihemagglutinin (anti-HA) antibody (IgG) levels, induced both Th1 (interleukin 2 [IL-2] and gamma interferon [IFN-γ])- and Th2 (IL-4)-type cytokines, promoted the proliferation of peripheral blood lymphocytes, and increased populations of CD3(+) T cells and their subsets CD4(+) (CD3(+) CD4(+)) T cells and CD8(+) (CD3(+) CD8(+)) T cells. Furthermore, a virus challenge experiment revealed that BP5 contributes to protection against homologous avian influenza virus challenge by reducing viral replication in chicken lungs. This study indicates that the combination of inactivated AIVs and BP5 gives a strong immune response at both the humoral and cellular levels and implies that BP5 is a novel immunoadjuvant suitable for vaccine design.